Tolerability aspects in duloxetine-treated patients with depression: should one use a lower starting dose in clinical practice?

Bibliography

• Gartlehner G, Hansen RA, Carey TS, Discontinuation rates for selective serotonin reuptake inhibitors and other second generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Int Clin Psychopharmacol 2005;20:59-69
   PubMed Web of Science ®Google Scholar
• Linden M, Gothe H, Dittmann RW, Schaaf B. Early termination of antidepressant drug treatment. J Clin Psychopharmacol 2000;20:523-30
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Enzlin P, Dewe W, Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62(22 Suppl):30-3
   PubMed Web of Science ®Google Scholar
• Lawrenson RA, Tyrer F, Newson RB, Farmer RD. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and trycyclic antidepressants compared. J Affect Disord 2000;59:149-57
   PubMed Web of Science ®Google Scholar
• Whitmyer VG, Dunner DL, Kornstein SG, A comparison of initial duloxetine dosing strategies in patients with depressive disorder. J Clin Psychiatry 2007;68:1921-30
   PubMed Web of Science ®Google Scholar
• Dunner DL, Wohlreich MM, Mallinckrodt CG, Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60 mg QD starting doses. Curr Ther Res 2005;66:522-40
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Prakash A, Andorn AC, Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006;40:337-48
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Lohr KN, Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;20:415-26
   Google Scholar
• Hudson JI, Wohlreich MM, Kajdasz DK, Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005;20:327-41
   PubMed Web of Science ®Google Scholar
• Davidson JR, Wittchen HU, Llorca PM, Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2008;18:673-81
   PubMed Web of Science ®Google Scholar
• Perahia DG, Maina G, Thase M, Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:706-16
   PubMed Web of Science ®Google Scholar
• Gaynor PJ, Gopal M, Zheng W, A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms. Curr Med Res Opin 2011;27:1849-58
   PubMed Web of Science ®Google Scholar
• Torta R, Leombruni P, Borio R, Castelli L. Duloxetine for the treatment of mood disorder in cancer patients: a 12-week case-control clinical trial. Hum Psychopharmacol Clin Exp 2011;26:291-9
   PubMed Web of Science ®Google Scholar
• Schneider E, Linden M, Weigmann H, Early reduction in painful physical symptoms is associated with improvements in long-term depression outcomes in patients treated with duloxetine. BMC Psychiatry 2011;11:150
   PubMed Web of Science ®Google Scholar
• Schotte K, Linden M. Correlates of low-dosage treatment with antidepressants by psychiatrists and general practioners. Pharmacoepidemiol Drug Saf 2007;16:675-80
   PubMed Web of Science ®Google Scholar
• WHO. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research (DCR-10). World Health Organization; Geneva: 1993
   Google Scholar
• Wendt G, Binz U, Muller AA. KUSTA (Kurz-Skala Stimmung/Aktivierung): a daily self-rating scale for depressive patients. Pharmacopsychiat 1985;18:118-22
   PubMed Web of Science ®Google Scholar
• Rush AJ, Gullion CM, Basco MR, The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med 1996;26:477-86
   PubMed Web of Science ®Google Scholar
• Grässlin Y. The inventory of depressive symptoms (IDS): validation of the self-rated assesment in German. Doctoral thesis, University of Freiburg, Dept. of Psychiatry. 2004; http://www.freidok.uni-freiburg.de/volltexte/1322/
   Google Scholar
• Weinstein MC, Berwick DM, Goldman PA, A comparison of three psychiatric screening tests using receiver operating characteristic (ROC) analysis. Med Care 1989;27:593-607.
   PubMed Web of Science ®Google Scholar
• D'Agostino RB. Tutorial in Biostatistics: propensity score methods for bias reduction in the comparison of a treatment to non-randomized control group. Stat Med 1989;17:2265-81
   Google Scholar
• Gahimer J, Wernicke J, Yalcin I, A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007;23:175-84
   PubMed Web of Science ®Google Scholar
• Brunton S, Wang F, Edwards SB, Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf 2010;33:393-407
   PubMed Web of Science ®Google Scholar
• Dittmann RW, Linden M, Osterheider M. Fluoxetine treatment and single psychotropic comedication: is there an increase in adverse event rates? Pharmacoepidemiol Drug Saf 1998;7:197-206
   PubMed Web of Science ®Google Scholar
• Wohlreich MM, Martinez JM, Mallinckrodt CH, An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 2005;25:552-60
   PubMed Web of Science ®Google Scholar
• Perahia DG, Quail D, Desaiah D, Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry 2008;69:95-105
   PubMed Web of Science ®Google Scholar
• Sagman D, McIntosh D, Lee MS, Attributes of response in depressed patients switched to treatment with duloxetine. Int J Clin Pract 2011;65:73-81
   PubMed Web of Science ®Google Scholar
• Perahia DG, Pritchett YL, Desaiah D, Raskin J. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 2006;21:311-17
   PubMed Web of Science ®Google Scholar
• Brecht S, Courtecuisse C, Debieuvre C, Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 2007;68:1707-16
   PubMed Web of Science ®Google Scholar
• Perahia DG, Quail D, Desaiah D, Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial responders: effects on painful physical symptoms of depression. J Psychiatr Res 2009;43:512-18
   PubMed Web of Science ®Google Scholar
• Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity - A literature review. Arch Intern Med 2003;163:2433-5.
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Reed C, Quail D, Presence and predictors of pain in depression: results from the FINDER study. J Affect Disord 2010;125:53-60
   PubMed Web of Science ®Google Scholar
• Garcia-Cebrian A, Gandhi P, Demyttenaere K, Peveler R. The association of depression and painful physical symptoms - a review of the European literature. Eur Psychiatry 2006;21:379-88
   PubMed Web of Science ®Google Scholar
• DGPPN, BAK, KBV, AWMF, AkdA, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) fur die Leitliniengruppe Unipolare Depression*. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Kurzfassung, 1. Auflage 2009. DGPPN, AZQ, AWMF - Berlin, Dusseldorf. 2009. Available from: http://www.depression.versorgungsleitlinien.de/ [Last accessed 06 Feburary 2012]
   Google Scholar
• Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol 1998;38:1003-9
   PubMed Web of Science ®Google Scholar
• Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The exampleof drug-induced long QT syndrome. Drug Saf 2001;24:575-85
   PubMed Web of Science ®Google Scholar
• Stewart DE, Wohlreich MM, Mallinckrodt CH, Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. J Affect Disord 2006;94:183-9
   PubMed Web of Science ®Google Scholar
• Nantz E, Liu-Seifert H, Skljarevski V. Predictors of premature discontinuation of treatment in multiple disease states. Patient Prefer Adherence 2009;3:31-43
   PubMed Web of Science ®Google Scholar
• Essock SM, Drake RE, Frank RG, McGuire TG. Randomized controlled trials in evidence-based mental health care: getting the right answer to the right question. Schizophr Bull 2003;29:115-23
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
   PubMed Web of Science ®Google Scholar